Effective acute stroke treatment beyond approval limitations: Intravenous thrombolysis within an extended time window (3-6 h) and in old patients (aged 80 or older);Effektive schlaganfalltherapie jenseits der zulassungsbeschränkungen: Intravenöse thrombolyse im erweiterten zeitfenster (> 3 h) und bei alten patienten (≥80 J.)

Fortschritte der Neurologie Psychiatrie

Volumn 75, Issue 6, 2007, Pages 343-350

  Thomalla, Götz ^a   Kohrmann M ^b   Rother J ^c   Schellinger, P D ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c KLINIKUM MINDEN   (Germany)

Author keywords

Aged, 80 and over; Diffusion and perfusion weighted MRI; Stroke, acute; Thrombolytic therapy

Indexed keywords

DESMOTEPLASE; FIBRINOLYTIC AGENT; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR;

AGED; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; FIBRINOLYTIC THERAPY; HUMAN; MORTALITY; PATIENT SELECTION; PROGNOSIS; REVIEW; STROKE; TIME; CEREBROVASCULAR ACCIDENT; INTRAVENOUS DRUG ADMINISTRATION;

AGED, 80 AND OVER; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; PLASMINOGEN ACTIVATORS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34447504623     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-959182     Document Type: Review

References (57)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587
2. Hacke W, Donnan G, Fieschi C, Kaste M, Kummer R von, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-774
3. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 2003; 34: 2847-2850
4. Audebert HJ, Kukla C, Vatankhah B, Gotzler B, Schenkel J, Hofer S, Furst A, Haberl RL. Comparison of tissue plasminogen activator administration management between Telestroke Network hospitals and academic stroke centers: the Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany. Stroke 2006; 37: 1822-1827
5. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004; 61: 346-350
6. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 2001; 32: 1832-1840
7. Nadeau JO, Shi S, Fang J, Kapral MK, Richards JA, Silver FL, Hill MD. TPA use for stroke in the Registry of the Canadian Stroke Network. Can J Neurol Sci 2005; 32: 433-439
8. Wang DZ, Rose JA Honings DS, Garwacki DJ, Milbrandt JC. Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. Stroke 2000; 31: 77-81
9. Weimar C, Kraywinkel K, Maschke M, Diener HC. Intravenous Thrombolysis in German Stroke Units before and after Regulatory Approval of Recombinant Tissue Plasminogen Activator. Cerebrovasc Dis 2006; 22: 429-431
10. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001; 56: 1015-1020
11. Heuschmann PU, Berger K, Misselwitz B, Hermanek P, Leffmann C, Adelmann M, Buecker-Nott HJ, Rother J, Neundoerfer B, Kolominsky-Rabas PL. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke 2003; 34: 1106-1113
12. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0-to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators. Stroke 2000; 31: 811-816
13. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Jama 1999; 282: 2019-2026
14. Hacke W, Kaste M, Fieschi C, Kummer R von, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-1251
15. Baron JC, Kummer R von, Zoppo GJ del. Treatment of acute ischemic stroke. Challenging the concept of a rigid and universal time window. Stroke 1995; 26: 2219-2221
16. Warach S. Thrombolysis in stroke beyond three hours: Targeting patients with diffusion and perfusion MRI. Ann Neurol 2002; 51: 11-13
17. Rother J. CTand MRI in the diagnosis of acute stroke and their role in thrombolysis. Thromb Res 2001; 103: S125-133
18. Schellinger PD, Fiebach JB, Hacke W. Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke 2003; 34: 575-583
19. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prouro-kinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism [see comment]. Jama 1999; 282: 2003-2011
20. Derex L, Nighoghossian N, Hermier M, Adeleine P, Berthezene Y, Philippeau F, Honnorat J, Froment JC, Trouillas P. Influence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator. J Neurol Sci 2004; 225: 3-9
21. Nighoghossian N, Hermier M, Adeleine P, Derex L, Dugor JF, Philippeau F, Ylmaz H, Honnorat J, Dardel P, Berthezene Y, Froment JC, Trouillas P. Baseline magnetic resonance imaging parameters and stroke outcome in patients treated by intravenous tissue plasminogen activator. Stroke 2003; 34: 458-463
22. Parsons MW, Barber PA, Chalk J, Darby DG, Rose S, Desmond PM, Gerraty RP, Tress BM, Wright PM, Donnan GA, Davis SM. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002; 51: 28-37
23. Ribo M, Molina CA, Rovira A, Quintana M, Delgado P, Montaner J, Grive E, Arenillas JF, Alvarez-Sabin J. Safety and Efficacy of Intravenous Tissue Plasminogen Activator Stroke Treatment in the 3- to 6-Hour Window Using Multimodal Transcranial Doppler/MRI Selection Protocol. Stroke 2005; 36: 602-606
24. Rother J, Schellinger PD, Gass A, Siebler M, Villringer A, Fiebach JB, Fiehler J, Jansen O, Kucinski T, Schoder V, Szabo K, Junge-Hulsing GJ, Hennerici M, Zeumer H, Sartor K, Weiller C, Hacke W. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours. Stroke 2002; 33: 2438-2445
25. Schellinger PD, Jansen O, Fiebach JB, Heiland S, Steiner T, Schwab S, Pohlers O, Ryssel H, Sartor K, Hacke W. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI. Stroke 2000; 31: 1318-1328
26. Thomalla G, Schwark C, Sobesky J, Bluhmki E, Fiebach JB, Fiehler J, Zaro Weber O, Kucinski T, Juettler E, Ringleb PA, Zeumer H, Weiller C, Hacke W, Schellinger PD, Rother J. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 2006; 37: 852-858
27. Kohrmann M, Juttler E, Fiebach JB, Huttner HB, Siebert S, Schwark C, Ringleb PA, Schellinger PD, Hacke W. MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol 2006; 5: 661-667
28. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37: 1227-1231
29. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 66-73, Epub 2004 Nov 2029
30. Diener HCH. Leitlinien für Diagnostik und Therapie in der Neurologie Therapieempfehlungen der 'Kommission Leitlinien' der Deutschen Gesellschaft für Neurologie. ed. 3., überarb. Aufl. Stuttgart, New York, Georg Thieme Verlag, 2005
31. Hjort N, Butcher K, Davis SM, Kidwell CS, Koroshetz WJ, Rother J, Schellinger PD, Warach S, Ostergaard L. Magnetic resonance imaging criteria for thrombolysis in acute cerebral infarct. Stroke 2005; 36: 388-397, Epub 2004 Dec 2023
32. Davis SM, Donnan GA, Butcher KS, Parsons M. Selection of thrombolytic therapy beyond 3h using magnetic resonance imaging. Curr Opin Neurol 2005; 18: 47-52
33. Rother J, Jonetz-Mentzel L, Fiala A, Rekhenbach JR, Herzau M, Kaiser WA, Weiller C. Hemodynamic assessment of acute stroke using dynamic single-slice computed tomographic perfusion imaging. Arch Neurol 2000; 57: 1161-1166
34. Wintermark M, Reichhart M, Cuisenaire O, Maeder P, Thiran JP, Schnyder P, Bogousslavsky J, Meuli R. Comparison of admission perfusion computed tomography and qualitative diffusion- and perfusion-weighted magnetic resonance imaging in acute stroke patients. Stroke 2002; 33: 2025-2031
35. Kaste M. Reborn workhorse, CT, pulls the wagon toward thrombolysis beyond 3 hours. Stroke 2004; 35: 357-359
36. Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, Katalinic A, Lang E, Gassmann KG, von Stockert TR. A prospective community-based study of stroke in Germany-the Erlangen Stroke Project (ESPro): incidence and case fatality at 1, 3, and 12 months. Stroke 1998; 29: 2501-2506
37. Di Carlo A, Lamassa M, Pracucci G, Basile AM, Trefoloni G, Vanni P, Wolfe CD, Tilling K, Ebrahim S, Inzitari D. Stroke in the very old : clinical presentation and determinants of 3-month functional outcome: A European perspective. European BIOMED Study of Stroke Care Group. Stroke 1999; 30: 2313-2319
38. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project - 1981 - 86.2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 1990; 53: 16-22
39. Kammersgaard LP, Jorgensen HS, Reith J, Nakayama H, Pedersen PM, Olsen TS. Short- and long-term prognosis for very old stroke patients. The Copenhagen Stroke Study. Age Ageing 2004; 33: 149-154
40. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997; 28: 2109-2118
41. Subgroup analysis of the NINDS t-PA Stroke Trial. Generalized efficacy of t-PA for acute stroke. Stroke 1997; 28: 2119-2125
42. Berrouschot J, Rother J, Glahn J, Kucinski T, Fiehler J, Thomalla G. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or = 80 years) stroke patients. Stroke 2005; 36: 2421-2425
43. Chen CI, Iguchi Y, Grotta JQ Garami Z, Uchino K, Shaltoni H, Alexandrov AV. Intravenous TPA for very old stroke patients. Eur Neurol 2005; 54: 140-144
44. Engelter ST, Reichhart M, Sekoranja L, Georgiadis D, Baumann A, Weder B, Muller F, Luthy R, Arnold M, Michel P, Mattle HP, Tettenborn B, Hungerbuhler HJ, Baumgartner RW, Sztajzel R, Bogousslavsky J, Lyrer PA. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology 2005; 65: 1795-1798
45. Mouradian MS, Senthilselvan A, Jickling G, McCombe JA, Emery DJ, Dean N, Shuaib A. Intravenous rt-PA for acute stroke: comparing its effectiveness in younger and older patients. J Neurol Neurosurg Psychiatry 2005; 76: 1234-1237
46. Simon JE, Sandler DL, Pexman JH, Hill MD, Buchan AM. Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischaemic stroke? - The Calgary experience. Age Ageing 2004; 33: 143-149
47. Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry 2006; 77: 826-829
48. Tanne D, Bates VE, Verro P, Kasner SE, Binder JR, Patel SC, Mansbach HH, Daley S, Schultz LR, Karanjia PN, Scott P, Dayno JM, Vereczkey-Porter K, Benesch C, Book D, Coplin WM, Dulli D, Levine SR. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group. Neurology 1999; 53: 424-427
49. Oostenhrugge RJ van, Hupperts RM, Lodder J. Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre. J Neurol Neurosurg Psychiatry 2006; 77: 375-377
50. Parnetti L, Silvestrelli G, Lanari A, Tambasco N, Capocchi G, Agnelli G. Efficacy of thrombolytic (rt-PA) therapy in old stroke patients: the Perugia Stroke Unit experience. Clin Exp Hypertens 2006; 28: 397-404
51. Gorman MJ, Tanne D, Lewandowski CA. Centenarian stroke treated with tissue-type plasminogen activator. Cerebrovasc Dis 2002; 13: 285-287
52. Sharma JC, Fletchers, Vassallo M. Strokes in the elderly - higher acute and 3-month mortality - an explanation. Cerebrovasc Dis 1999; 9: 2-9
53. Anderson JL, Karagounis L, Allen A, Bradford MJ, Menlove RL, Pryor TA. Older age and elevated blood pressure are risk factors for intracerebral hemorrhage after thrombolysis. Am J Cardiol 1991; 68: 166-170
54. Tanne D, Gorman MJ, Bates VE, Kasner SE, Scott P, Verro P, Binder JR, Dayno JM, Schultz LR, Levine SR. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experience. Stroke 2000; 31: 370-375
55. The Third International Stroke Trial (Thrombolysis). (1ST-3). http://www.dcn.ed.ac.uk/ist3 [Stand 14.02.2007]
56. Desmoteplase in Acute Ischemic Stroke-2 (DIAS-2) http://paiondias. 01kunden.net/cgi-bin/WebObjects/paionDias.woa/1/wa/DirectoryWithld/1000009.html [Stand 14.02.2007]
57. Marx P, Hartmann A, Leistner S, Nohr R, Koennecke HC. [Prerequisites, indications and contraindications of IV-lysis of ischemic stroke with rt-PA]. Fortschr Neurol Psychiatr 2001; 69: 346-352